The effect of remdesivir on differentiation of human mesenchymal stem cells into osteoblast

Backgrounds: Remdesivir is a phosphoramidate prodrug of the C-adenosine analog GS-۴۴۱۵۲۴that is metabolized within cells into the alanine metabolite (GS-۷۰۴۲۷۷) and further processedinto the mono-phosphate derivative and ultimately into the active nucleoside triphosphate (NTP)derivative. Nucleoside analogs require active cell uptake by nucleoside vectors and intracellularactivation by cellular and viral kinases to become their active NTP metabolites. RemedSivirprodrug (GS-۵۷۳۴) has a relatively short systemic half-life (۰.۹ hours) and is rapidly convertedintracellularly to several intermediate metabolites (GS-۷۰۴۲۷۷) and GS-۴۴۷۱۵۲۴. It is widelyused to treat Coronavirus disease, but the evidence suggests that the drug has serious side effects.Materials and Methods: In the present investigation, we decided to study the effect of this drugon the differentiation of human mesenchymal stem cells into osteoblasts. Another goal of theproject was to investigate some blood factors in mice that were injected with Remdesivir. Bonemarrow-derived mesenchymal stem cells were exposed to the drug at doses used to treatCOVID-۱۹ for ۲۸ days.Results: This study showed that Remdesivir increased the intensity of staining of cells withAlizarin red dye and increased the expression of the alkaline phosphatase gene in bone culturemedia.Conclusion: It can be concluded that Remdesivir increases the differentiation of stem cells in thebody into osteoblast while also affecting some blood and serum factors.

کلیدواژه ها:

Remdesivir ، Stem cells ، Osteoblast ، Coronavirus disease ، Blood cells